PF-08634404 + Chemotherapy for Colorectal Cancer

This trial tests a new medicine, PF-08634404, for individuals with colorectal cancer that has spread or returned after previous treatments. The study aims to determine if adding this drug to standard chemotherapy can improve outcomes. Participants will receive either the new drug with chemotherapy or another approved treatment, Bevacizumab, with chemotherapy. Individuals with metastatic colorectal cancer who are in good health might be suitable for this study. As a Phase 3 trial, this study is the final step before potential FDA approval, offering participants the opportunity to contribute to a treatment that could soon become widely available.

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Studies have shown that PF-08634404 is generally well-tolerated when combined with chemotherapy for colorectal cancer. Research indicates that most patients handled the treatment without serious side effects. Common reactions included tiredness, nausea, and mild skin issues, which are typical with cancer treatments.

The second treatment option, Bevacizumab, already approved for colorectal cancer, has a well-known safety record. It is usually well-tolerated, though some patients might experience high blood pressure, fatigue, or minor bleeding.

Researchers are excited about PF-08634404 for colorectal cancer because it introduces a novel mechanism of action by potentially targeting specific cancer pathways that current treatments do not address. Unlike the standard care options, such as bevacizumab, which primarily inhibit blood vessel growth to the tumor, PF-08634404 might directly interfere with the cancer cell's growth processes. This unique approach could offer a more targeted treatment, possibly leading to better outcomes and fewer side effects.

Research has shown that PF-08634404, when combined with chemotherapy, might benefit people with metastatic colorectal cancer. Studies suggest this combination could extend the period during which the cancer does not worsen and improve survival rates. In this trial, participants will receive either PF-08634404 with chemotherapy or Bevacizumab with chemotherapy. Researchers are comparing this new medicine to Bevacizumab, a common treatment, to determine its effectiveness. Early results are promising, indicating that PF-08634404 could be a viable option for those whose cancer has returned or spread after previous treatments.¹²⁴⁶⁷